Genmab — Februar 2020
-
it is in the questions somewhere https://old.nasdaq.com/article/genmab-as-gmab-q4-2019-earnings-call-transcript-cm1284238
-
And even in the absence of [Technical Issues], we will actually accelerate -- we will accelerate the program ourselves with multiple Phase 2, so potentially even Phase 3 starting up in the second half of this year. - Antager der i klammen skulle have stået partner.
-
Netop Bulder..Lige det punkt var godt at få belyst på vores Q&A.
-
Tak for det.

-
Det er første gang jeg har set et så kort svar fra Jan.
-
Spændende Q&A, stor tak til Helge for at arrangere den. Kl. 14.28: Ofatumumab til behandling af MS, priority review voucher, den kan komme på markedet i 3. kvartal. (og så var det nok Novartis, der købte den af Bavarian i slutningen af januar)
-
Enjoy the first Q&A from Proinvestor's new office and headquarters in Rødovre shopping center. https://www.proinvestor.com/index.php?p=debat_1&postid=82095
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind